An observational study to describe treatment patterns of patients with BRAFV600E mutant metastatic non-small cell lung cancer (OCTOPUS).

An observational study describing diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice, to assess treatment effectiveness and quality of life.

Hide study title
Status :
Type of study
Min. Age
Years old
Max. Age

Brief summary

Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer diagnoses. Approximately 1-2% of patients affected by a NSCLC have a specific genetic mutation called BRAFV600E mutation.
In a context of a lack of information, it would be useful for the future patients to provide an overview of diagnosis and treatment processes using data of patients already affected by this cancer.
Therefore, the purpose of this study is to identify treatment patterns given to patients with mutated BRAFV600E mNSCLC and to describe the efficacy of treatments and patients’ quality of life in routine practice.

Therapeutic area :
Disease :
Non small cell lung cancer (NSCLC)
Study medication :
First and second-line treatments for metastatic non-small cell lung cancer
Phase : RWE
Start Date :
23 June 2022
End Date / Planned study Completion Date :
June 2025
Study ID : NIS12500 Number : NCT05546905
Countries :
United Kingdom

Contact Us

Need more information, click on the button to have access to the contact form.

Contact Us

Access to Lay Protocol Synopsis

Un résumé du protocole rédigé en termes simples et décrivant les objectifs de l’étude vous est proposé  

Send by email